Intervention Protocol

Maintenance bioimmunotherapy for epithelial ovarian cancer

  1. Ling Mei,
  2. Hui Chen,
  3. Fuxia Chen,
  4. Dan Feng,
  5. Fang Fang*

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 11 MAY 2011

Assessed as up-to-date: 11 APR 2011

DOI: 10.1002/14651858.CD009137


How to Cite

Mei L, Chen H, Chen F, Feng D, Fang F. Maintenance bioimmunotherapy for epithelial ovarian cancer (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No.: CD009137. DOI: 10.1002/14651858.CD009137.

Author Information

  1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

*Fang Fang, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. ffmn59@163.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 11 MAY 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness and toxicity of maintenance bioimmunotherapy available for epithelial ovarian cancer and to evaluate the impact on the quality of life (QoL) of maintenance bioimmunotherapy. We will update this review once new treatments are available, but the first step is to evaluate interferon-alpha, matrix metalloprotease inhibitor, monoclonal antibodies, and some radioimmunotherapies, which have been studied by phase trials.